FGFR2 amplification is also a common FGFR aberration, occurring in 5–10% of breast cancers and 4% of TNBCs, and FGFR2 signaling drives resistance to Tamoxifen in ER+ disease [30, 31]. Here, FGFR2 is linked to breast cancer.